Bluejay Diagnostics (BJDX) Net Cash Flow (2020 - 2026)

Bluejay Diagnostics (BJDX) has 7 years of Net Cash Flow data on file, last reported at -$1.5 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 24.84% year-over-year to -$1.5 million; the trailing twelve-month figure through Mar 2026 stood at $742089.0 (up 63.12% YoY), and the FY2025 full-year result was $862930.0, down 58.78% from the prior year.
• Net Cash Flow eased to -$1.5 million in Q1 2026, from $2.3 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $5.4 million in Q2 2024 to a low of -$3.3 million in Q1 2023.
• A 5-year average of -$893980.1 and a median of -$1.5 million in 2026 frame the typical range for Net Cash Flow.
• Peak annual rise in Net Cash Flow reached 420.98% in 2024, while the deepest fall reached 9711.14% in 2024.
• Tracing BJDX's Net Cash Flow over 5 years: stood at -$3.2 million in 2022, then gained by 9.87% to -$2.9 million in 2023, then soared by 49.32% to -$1.5 million in 2024, then jumped by 255.2% to $2.3 million in 2025, then plunged by 165.61% to -$1.5 million in 2026.
• Business Quant data shows BJDX's Net Cash Flow at -$1.5 million in Q1 2026, $2.3 million in Q4 2025, and -$1.4 million in Q3 2025.